{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:03:39Z","timestamp":1774364619124,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tetraphase Pharmaceuticals Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.clinthera.2019.08.005","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T07:12:33Z","timestamp":1567840353000},"page":"2162-2170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration"],"prefix":"10.1016","volume":"41","author":[{"given":"Lindsay M.","family":"Avery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.08.005_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3389\/fmicb.2019.00539","article-title":"Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review","volume":"10","author":"Mulani","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.clinthera.2019.08.005_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.clinthera.2019.08.005_bib3","series-title":"XeravaTM (Eravacycline) for Injection (Package Insert)","year":"2018"},{"key":"10.1016\/j.clinthera.2019.08.005_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anaerobe.2018.06.016","article-title":"In\u00a0vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species","volume":"52","author":"Goldstein","year":"2018","journal-title":"Anaerobe"},{"key":"10.1016\/j.clinthera.2019.08.005_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02206-17","article-title":"Evaluation of the in\u00a0vitro activity oferavacycline against a broad spectrum of recent clinical anaerobic isolates","volume":"62","author":"Snydman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.08.005_bib6","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In\u00a0vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.08.005_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.clinthera.2019.08.005_bib8","series-title":"Microbiological Efficacy of Eravacycline against Enterobacteriaceae and Acinetobacter Baumannii, Including MDR Isolates: A Pooled Analysis from IGNITE1 and IGNITE4, Two Phase 3 Trials of Complicated Intra-abdominal Infection","author":"Ditch","year":"2018"},{"key":"10.1016\/j.clinthera.2019.08.005_bib9","article-title":"The efficacy and safety of eravacycline in the treatment of complicated intra-abdominal infections: a systemic review and meta-analysis of randomized controlled trials","volume":"8","author":"Lan","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.clinthera.2019.08.005_bib10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clinthera.2019.08.005_bib11","doi-asserted-by":"crossref","first-page":"ofx063","DOI":"10.1093\/ofid\/ofx063","article-title":"Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials","volume":"4","author":"Alexander","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2019.08.005_bib12","first-page":"939","article-title":"Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets","volume":"34","author":"Allen","year":"1977","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clinthera.2017.12.007","article-title":"Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration","volume":"40","author":"Kidd","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2019.08.005_bib14","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.2146\/ajhp170123","article-title":"Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Monogue","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib15","first-page":"1716","article-title":"Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection","volume":"49","author":"Trissel","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2146\/ajhp170839","article-title":"Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration","volume":"75","author":"Asempa","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ajhp\/54.11.1287","article-title":"Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration","volume":"54","author":"Trissel","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib18","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2146\/ajhp080059","article-title":"Drug incompatibility chemistry","volume":"66","author":"Newton","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/00000542-200510000-00026","article-title":"Propofol: the challenges of formulation","volume":"103","author":"Baker","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1016\/j.clinthera.2019.08.005_bib20","series-title":"Assessment Report for Mycamine","year":"2008"},{"key":"10.1016\/j.clinthera.2019.08.005_bib21","series-title":"Furosemide Injection, USP (Package Insert)","year":"2016"},{"key":"10.1016\/j.clinthera.2019.08.005_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00003495-197611010-00004","article-title":"Interactions with the absorption of tetracyclines","volume":"11","author":"Neuvonen","year":"1976","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2019.08.005_bib23","doi-asserted-by":"crossref","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","article-title":"Tetracyclines: a pleitropic family of compounds with promising therapeutic properties: review of the literature","volume":"299","author":"Griffin","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clinthera.2019.08.005_bib24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.37.7.1393","article-title":"Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples","volume":"37","author":"Nikaido","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2019.08.005_bib25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ajhp\/62.8.834","article-title":"Compatibility of anidulafungin with other drugs during simulated Y-site administration","volume":"62","author":"Trissel","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib26","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2146\/ajhp100606","article-title":"Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration","volume":"68","author":"Singh","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2019.08.005_bib27","first-page":"173","article-title":"Clinical implications of intravenous drug incompatibilities in critically ill patients","volume":"38","author":"Benlabed","year":"2019","journal-title":"Anaesth Crit Care Pain Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819303996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:55Z","timestamp":1758963175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819303996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0149291819303996"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.08.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}